6533b832fe1ef96bd129ae98
RESEARCH PRODUCT
MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk
Paolo M. ComoglioCristina BasilicoChiara ModicaElisa VignaDora Tortarolosubject
0301 basic medicineStromal cellpancreatic cancerReviewHGF; MET; Metastasis; Pancreatic cancer; Target therapy; Tumor microenvironment; Animals; Hepatocyte Growth Factor; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins c-metCatalysisMetastasisInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicinePancreatic cancermedicineAnimalsHumansmetastasistumor microenvironmentHGFPhysical and Theoretical ChemistryNeoplasm MetastasisMolecular Biologylcsh:QH301-705.5SpectroscopyTumor microenvironmentbusiness.industryHepatocyte Growth Factortarget therapyOrganic ChemistryGeneral MedicineProto-Oncogene Proteins c-metmedicine.diseaseComputer Science ApplicationsPancreatic Neoplasms030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Tumor progressionHepatocyte Growth Factor Receptor030220 oncology & carcinogenesisCancer cellCancer researchMETHepatocyte growth factorbusinessmedicine.drugdescription
The ‘onco-receptor’ MET (Hepatocyte Growth Factor Receptor) is involved in the activation of the invasive growth program that is essential during embryonic development and critical for wound healing and organ regeneration during adult life. When aberrantly activated, MET and its stroma-secreted ligand HGF (Hepatocyte Growth Factor) concur to tumor onset, progression, and metastasis in solid tumors, thus representing a relevant target for cancer precision medicine. In the vast majority of tumors, wild-type MET behaves as a ‘stress-response’ gene, and relies on ligand stimulation to sustain cancer cell ‘scattering’, invasion, and protection form apoptosis. Moreover, the MET/HGF axis is involved in the crosstalk between cancer cells and the surrounding microenvironment. Pancreatic cancer (namely, pancreatic ductal adenocarcinoma, PDAC) is an aggressive malignancy characterized by an abundant stromal compartment that is associated with early metastases and resistance to conventional and targeted therapies. Here, we discuss the role of the MET/HGF axis in tumor progression and dissemination considering as a model pancreatic cancer, and provide a proof of concept for the application of dual MET/HGF inhibition as an adjuvant therapy in pancreatic cancer patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-12-07 | International Journal of Molecular Sciences |